BR112022013298A2 - Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos - Google Patents
Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmosInfo
- Publication number
- BR112022013298A2 BR112022013298A2 BR112022013298A BR112022013298A BR112022013298A2 BR 112022013298 A2 BR112022013298 A2 BR 112022013298A2 BR 112022013298 A BR112022013298 A BR 112022013298A BR 112022013298 A BR112022013298 A BR 112022013298A BR 112022013298 A2 BR112022013298 A2 BR 112022013298A2
- Authority
- BR
- Brazil
- Prior art keywords
- tigit
- antibodies
- methods
- understand
- tigit antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020071340 | 2020-01-10 | ||
| PCT/CN2021/070899 WO2021139776A1 (en) | 2020-01-10 | 2021-01-08 | Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013298A2 true BR112022013298A2 (pt) | 2022-09-06 |
Family
ID=76787748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013298A BR112022013298A2 (pt) | 2020-01-10 | 2021-01-08 | Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12415858B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4087862A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7840852B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220131260A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115066431B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021205565B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022013298A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3164283A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021139776A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202208798B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110818795B (zh) * | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
| WO2022268168A1 (zh) * | 2021-06-23 | 2022-12-29 | 迈威(上海)生物科技股份有限公司 | 靶向lag-3和pd-l1的新型双特异抗体及其应用 |
| CN120590537A (zh) * | 2021-12-31 | 2025-09-05 | 南京维立志博生物科技股份有限公司 | 靶向tigit的双特异性抗体 |
| TW202417512A (zh) * | 2022-10-17 | 2024-05-01 | 英屬開曼群島商百濟神州有限公司 | 含有抗tigit抗體的配製物及其使用方法 |
| WO2025170315A1 (ko) * | 2024-02-05 | 2025-08-14 | 주식회사 트리오어 | 이중 기능 도메인을 포함하는 융합단백질 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
| SG10202007764TA (en) | 2015-09-25 | 2020-09-29 | Genentech Inc | Anti-tigit antibodies and methods of use |
| US10544222B2 (en) * | 2015-11-18 | 2020-01-28 | Merck Sharp & Dohme Corp. | PD1/CTLA4 binders |
| KR102379464B1 (ko) * | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3565839A4 (en) * | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | CHECKPOINT REGULATOR ANTAGONISTS |
| US11673954B2 (en) | 2017-11-17 | 2023-06-13 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-L1 |
| CN109966487B (zh) * | 2017-12-28 | 2023-08-25 | 上海复宏汉霖生物制药有限公司 | 一种包含抗pd-l1单克隆抗体的药物配制剂 |
| SG11202004521QA (en) * | 2018-02-06 | 2020-06-29 | I Mab Biopharma Us Ltd | Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof |
| CN110818795B (zh) * | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
-
2021
- 2021-01-08 WO PCT/CN2021/070899 patent/WO2021139776A1/en not_active Ceased
- 2021-01-08 JP JP2022542268A patent/JP7840852B2/ja active Active
- 2021-01-08 BR BR112022013298A patent/BR112022013298A2/pt unknown
- 2021-01-08 AU AU2021205565A patent/AU2021205565B2/en active Active
- 2021-01-08 KR KR1020227027448A patent/KR20220131260A/ko active Pending
- 2021-01-08 EP EP21738025.2A patent/EP4087862A4/en active Pending
- 2021-01-08 CA CA3164283A patent/CA3164283A1/en active Pending
- 2021-01-08 CN CN202180008450.3A patent/CN115066431B/zh active Active
-
2022
- 2022-07-08 US US17/811,541 patent/US12415858B2/en active Active
- 2022-08-05 ZA ZA2022/08798A patent/ZA202208798B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115066431B (zh) | 2026-07-14 |
| CN115066431A (zh) | 2022-09-16 |
| AU2021205565A1 (en) | 2022-07-28 |
| ZA202208798B (en) | 2023-03-29 |
| EP4087862A4 (en) | 2024-01-10 |
| KR20220131260A (ko) | 2022-09-27 |
| JP2023509214A (ja) | 2023-03-07 |
| AU2021205565B2 (en) | 2026-05-07 |
| WO2021139776A1 (en) | 2021-07-15 |
| JP7840852B2 (ja) | 2026-04-06 |
| EP4087862A1 (en) | 2022-11-16 |
| CA3164283A1 (en) | 2021-07-15 |
| US12415858B2 (en) | 2025-09-16 |
| US20230037911A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013545A2 (pt) | Anticorpos anti-tigit e método de uso | |
| BR112022013403A2 (pt) | Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos | |
| BR112022013633A2 (pt) | Anticorpos multiespecíficos que ligam tanto células mait quanto tumorais | |
| BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
| BR112019002168A2 (pt) | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina | |
| MX2023006212A (es) | Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivacion basado en tirosina de inmunorreceptor e inmunoglobulina (tigit). | |
| MX2021002002A (es) | Anticuerpos anti inmunorreceptor de celulas t con dominios ig y motivo inhibidor inmunorreceptor basado en tirosina (tigit). | |
| BR112014009030A2 (pt) | anticorpo de ligação a antígenos múltiplos estável | |
| BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
| EA202090247A1 (ru) | Антитела против cd166 и их применения | |
| BR112022011037A2 (pt) | Anticorpos ddr1 novos e usos dos mesmos | |
| BRPI0809665B8 (pt) | anticorpo monoclonal que se liga especificamente a endosialina | |
| BR112023003511A2 (pt) | Anticorpo biespecífico calr-cd3 mutante anticlivado e composição farmacêutica | |
| BR112021022171A2 (pt) | Anticorpo para tigit, seu uso e método para produzir o mesmo | |
| BR112023020193A2 (pt) | Proteína de ligação biespecífica, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, anticorpo biespecífico, métodos para tratamento ou prevenção de câncer e para intensificar uma resposta imunológica, e, usos de uma proteína de ligação biespecífica e de um ácido nucleico | |
| BR112012010266A2 (pt) | anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo | |
| BR112022019047A2 (pt) | Peptídeos de domínio knob autônomos | |
| BR112022005666A2 (pt) | Compostos engatadores de nk que se ligam a antígenos virais e métodos de uso | |
| BR112022000481A2 (pt) | Conjuntos de anticorpos e de ácidos nucleicos, vetor de expressão, célula hospedeira e métodos de pré-direcionamento de radioimunoterapia e de direcionamento de um radioisótopo | |
| BR112022008629A2 (pt) | Anticorpo isolado ou fragmento de ligação de antígeno do mesmo, polinucleotídeo isolado, vetor, célula isolada, composição farmacêutica, uso dos mesmos e método para inibir a ligação de igfbp3 ao receptor tmem219 | |
| BR112017017719A2 (pt) | imunoensaio homogêneo com compensação para sinal antecedente | |
| JP2018519525A5 (cg-RX-API-DMAC7.html) | ||
| BR112023021557A2 (pt) | Anticorpos anti-gpc3 e métodos de uso | |
| BR112022005909A2 (pt) | anticorpos isolados ou fragmento de ligação ao antígeno dos mesmos, método de preparação e usos dos mesmos, composição nucleotídica, vetor, célula hospedeira, composição farmacêutica, reagente para detecção de lif em amostras biológicas, e método exvivo para detectar o lif em amostras biológicas | |
| AR118594A1 (es) | Modificación por ingeniería genética de un anticuerpo para la fijación selectiva a cd47 en tumores |